Holen Sie sich die Stockscreener-App
81.57
7.03%
5.36
Handel nachbörslich:
79.95
-1.62
-1.99%
Schlusskurs vom Vortag:
$76.21
Offen:
$75.88
24-Stunden-Volumen:
351.46K
Relative Volume:
0.96
Marktkapitalisierung:
$1.19B
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$1.76B
KGV:
0.6873
EPS:
118.674
Netto-Cashflow:
$-149.23M
1W Leistung:
-8.23%
1M Leistung:
+3.08%
6M Leistung:
+457.93%
1J Leistung:
+460.23%
1-Tages-Spanne:
$75.00
$81.99
1-Wochen-Bereich:
$74.80
$90.80
52-Wochen-Spanne:
$10.80
$94.47
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
81.57 | 1.11B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences, Inc provides progress updates on the Inbrx-106 program and the expansion cohorts of the Ozekibart (Inbrx-109) program - marketscreener.com
Inhibrx Biosciences Provides Updates on Clinical Trials - TradingView — Track All Markets
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PR Newswire
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 6.6%Here's Why - MarketBeat
Understanding Momentum Shifts in (INBX) - news.stocktradersdaily.com
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX - MarketBeat
Franklin Resources Inc. Makes New $316,000 Investment in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences advances sarcoma research with ozekibart trial results - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5%Here's What Happened - MarketBeat
Inhibrx Biosciences, Inc. $INBX Shares Acquired by Kennedy Capital Management LLC - MarketBeat
With Inhibrx Biosciences Stock Surging, Have You Considered The Downside? - Trefis
Inhibrx Biosciences (NASDAQ:INBX) Trading 6.8% HigherWhat's Next? - MarketBeat
Is Inhibrx Biosciences Inc. stock a buy on dipsDollar Strength & Real-Time Market Trend Scan - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD By Investing.com - Investing.com Nigeria
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week HighHere's Why - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week High – Here’s Why - Defense World
Why Inhibrx Biosciences Inc. stock is favored by top institutions2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD - Investing.com
Avoiding Lag: Real-Time Signals in (INBX) Movement - news.stocktradersdaily.com
Inhibrx Biosciences boosts MSTS 2025 with platinum sponsorship - Traders Union
Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Earnings Report: How sustainable is Inhibrx Biosciences Inc. stock dividend payoutBond Market & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Inhibrx Biosciences unveils preclinical progress in glioblastoma treatment - Traders Union
Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN
Inhibrx Biosciences (NASDAQ:INBX) Sets New 1-Year HighHere's Why - MarketBeat
Inhibrx Biosciences stock hits all-time high at 87.4 USD By Investing.com - Investing.com Nigeria
Inhibrx Biosciences stock hits all-time high at 87.4 USD - Investing.com
Discipline and Rules-Based Execution in INBX Response - news.stocktradersdaily.com
Inhibrx Biosciences Inc. (INBX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Inhibrx Biosciences Inc. stock deliver shareholder value2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap - Seeking Alpha
What high frequency data says about Inhibrx Biosciences Inc.2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Inhibrx Biosciences (NASDAQ:INBX) Trading 7.4% HigherHere's What Happened - MarketBeat
How high can Inhibrx Biosciences Inc. stock go2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
Multi factor analysis applied to Inhibrx Biosciences Inc.Weekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
Inhibrx Biosciences Inc. stock daily chart insights2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
How to recover losses in Inhibrx Biosciences Inc. stock2025 Market Outlook & Safe Capital Growth Tips - newser.com
Inhibrx Biosciences stock rating maintained at Market Perform by Citizens - Investing.com South Africa
Is Inhibrx Biosciences Inc. stock a buy in volatile marketsWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Will Inhibrx Biosciences Inc. stock pay special dividendsJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Inhibrx Biosciences Inc (INBX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Why Inhibrx Biosciences Inc. stock appeals to analystsJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
What Wall Street predicts for Inhibrx Biosciences Inc. stock priceQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
Press Release: Inhibrx Reports Third Quarter 2025 Financial Results - 富途牛牛
Inhibrx Misses Estimates Even As New Cancer Drug Shows Promise - Finimize
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):